CNI-1493 for Treatment of Moderate to Severe Crohn's Disease

Summary

The purpose of this study is to determine whether CNI-1493 is safe and effective in the treatment of moderate to severe Crohn's Disease.

Timeline

Start

2002-06

Primary completion

2003-06

Completion

2003-06

Outcome

Outcome not reported

Stopped (Enrollment): “Unable to enroll into study.”

Publications

• Background Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B, Tytgat G, Peppelenbosch M, Van Deventer S. Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 2002 Jan;122(1):7-14. doi: 10.1053/gast.2002.30770.

Drugs

Indications